

DISCLOSURE OF SIGNIFICANT FINANCIAL INTEREST

Before completing, please read the Financial Conflict of Interest Policy for PHS or NSF Grants. The following disclosure is made pursuant to the requirements of the PHS rule "Responsibility of Applicants for Promoting Objectivity in Research for which Public Health Service Funding is Sought and Responsible Prospective" (42 CFR Part 50 and 45 CFR Part 94). This disclosure must be updated annually, and whenever new reportable significant financial interests are acquired.

DEFINITIONS

Significant Financial Interest: a) any equity interest in non-publically traded entities; (b) any reimbursed or sponsored travel (e.g. airfare, accommodation, per diem expenses); c) intellectual property rights and interests, upon receipt of income related to and/or; d) the following interest(s) which when aggregated exceed \$5,000: anything of monetary value, including but not limited to salary or other payments for services (e.g., consulting fees or honoraria) and any equity interest if any publically traded entity. The term does not include a) salary, royalties or other remuneration from College of the Holy Cross, b) income from seminars, lectures or teaching engagements sponsored by public or nonprofit entities, c) income from service on advisory committees or review panels for public or nonprofit entities, d) income from government entities or institutions of higher education, e) income from investment vehicles, such as mutual funds and retirement accounts, as long as the investigator does not directly control the investment decisions made in these vehicles.

Investigator: The Principal Investigator and any other person at the College, who is responsible for the design, conduct or reporting of research educational or service activities funded, or proposed for funding, by certain Federal Agencies. Typically this will include the Principal Investigators and co-Investigators, Sub-recipients and Collaborators. For the purpose of this disclosure requirement, the term "investigator" includes the investigator's spouse and dependent children.

<input type="checkbox"/> NO SIGNIFICANT FINANCIAL INTEREST TO DISCLOSE			
DISCLOSURE OF SIGNIFICANT FINANCIAL INTEREST*			
Investigator Name:	Department:	Source:	Total amount received from all sources below: \$ _____
TYPE OF ORGANIZATION			
<input type="checkbox"/> pharmaceutical firm <input type="checkbox"/> biotech firm <input type="checkbox"/> engineering firm <input type="checkbox"/> software firm <input type="checkbox"/> other _____			
NATURE OF REMUNERATION			
<input type="checkbox"/> salary <input type="checkbox"/> royalties <input type="checkbox"/> consulting <input type="checkbox"/> licensing <input type="checkbox"/> honoraria <input type="checkbox"/> reimbursed travel expenses <input type="checkbox"/> other _____			
TYPES OF HOLDING			
<input type="checkbox"/> stocks/stock options <input type="checkbox"/> patents/copyrights <input type="checkbox"/> other _____ estimated value \$ _____			
EQUITY INTEREST			
Enterprise or Entity: _____		Description: _____	
REIMBURSED OR SPONSORED TRAVEL EXPENSES within the last 12 months			
Purpose of the trip: _____ Sponsor: _____		Destination: _____ Duration: _____	
Type of payment: <input type="checkbox"/> gift <input type="checkbox"/> income		<input type="checkbox"/> Airfare <input type="checkbox"/> other transportation (limousine, taxi, etc.) <input type="checkbox"/> meals <input type="checkbox"/> hotel / other accommodation <input type="checkbox"/> other _____	
Value \$ _____ (If the organization above provided the reimbursement "in kind," please estimate)			
SIGNATURES			
Investigator's Signature:	Date:	Compliance Officer Signature:	Date:

*Please note: a separate form is required for each enterprise or entity in which a significant financial interest is identified. Supporting documents may be required.